Compare Arqit Quantum Inc (ARQQ) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs Cassava Sciences Inc — how do they compare? Arqit Quantum Inc trades at $23.44 (market cap $424.79M), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Arqit Quantum Inc is far larger — about 8.9× Cassava Sciences Inc's market cap, and Arqit Quantum Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | FLNA | |
|---|---|---|
Market Cap | $424.79M | $47.75M |
Sector | Technology | Health |
52-Week High | $58.27 | $4.64 |
52-Week Low | $11.78 | $0.87 |
Enterprise Value | $398.10M | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $24.10, up 6.59% today, with a bullish technical signal from moving averages. The company shows explosive revenue growth (829% YoY in H1 2026) but remains deeply unprofitable with a -4,508% net margin. Recent news highlights quantum-safe encryption partnerships with telecom and government clients, driving investor optimism despite significant financial losses.
Outlook remains speculative with high risk/reward profile. The quantum security market offers substantial growth potential, but ARQQ must demonstrate path to profitability amid heavy operating losses. Analyst consensus is divided (50% Buy, 50% Hold), reflecting uncertainty about timeline for sustainable operations.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
